Pulmonary fibrosis drug developer Avalyn files IPO
Avalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies.
Newsletters and Deep Dive digital magazine
Avalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies.
Gene variants could explain why some people lose more weight than others with GLP-1 drugs, and why some are more prone to side effects.
Our round-up of recent biotech venture capital financings includes nine-figure rounds for Syneron, Stipple Bio, and Sidewinder.
Jeito Capital has closed its second fund, raking in €1bn, which it claims is the largest ever raise for an independent European biopharma fund.
A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.
Editor's Picks
Newsletters and Deep Dive
digital magazine